The 2009 list of the top 20 pharmaceutical companies, ranked by IMS Health according to global prescription drug sales for the 12 months up to September 2009, shows that Teva, Novo Nordisk and Boehringer Ingelheim scored better in percent change than Big Pharma in those months.
IMS Health Top 20 pharmaceutical companies 2009
Home/Pharma News
|
Posted 23/04/2010
0
Post your comment
The data below does not take into account the large acquisitions by Pfizer and Merck, of Wyeth and Schering-Plough respectively, which were completed after September 2009.
| Company Sales | (billion US$) | % change |
| 1. Pfizer | 41.7 | (0.8) |
| 2. Novartis | 36.7 | 7.0 |
| 3. Sanofi-aventis | 35.1 | 3.3 |
| 4. GlaxoSmithKline | 34.3 | (3.4) |
| 5. AstraZeneca | 33.2 | 7.8 |
| 6. Roche | 31.3 | 8.6 |
| 7. Johnson & Johnson | 26.9 | (6.6) |
| 8. Merck & Co | 25.0 | (4.1) |
| 9. Eli Lilly | 19.6 | 8.3 |
| 10. Abbott | 19.4 | 5.5 |
| 11. Teva | 15.7 | 12.3 |
| 12. Bayer | 15.4 | 3.9 |
| 13. Wyeth | 14.8 | (2.3) |
| 14. Amgen | 14.8 | (3.1) |
| 15. Boehringer Ingelheim | 14.6 | 10.4 |
| 16. Takeda | 14.4 | 2.1 |
| 17. Bristol-Myers | 14.2 | 5.8 |
| 18. Schering-Plough | 13.1 | 4..3 |
| 19. Daiichi Sankyo | 8.5 | 3.1 |
| 20. Novo Nordisk | 8.2 | 11.6 |
References:
IMS Health
FACTBOX-The 20 largest pharmaceutical companies. Reuters. 2010 March 26.
Policies & Legislation
ANVISA and Danish Medicines Agency renew health regulatory collaboration
Colombia and Brazil introduce reforms to enhance healthcare regulation
Related content
Cuba and Russia plan first joint biopharmaceutical venture in 2025
Home/Pharma News Posted 27/05/2025
Sandoz–Henlius partner to commercialize oncology biosimilar ipilimumab
Home/Pharma News Posted 11/05/2025
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment